Science 37, Inc. (Science 37), developer of the Decentralized Clinical Trial Operating SystemTM, and LifeSci Acquisition II Corp. (NASDAQ: LSAQ) (LifeSci), a blank check company targeting the biopharma, medical technology, […]

The post Latham & Watkins Advises Science 37 in US$1.05 billion de-SPAC transaction with LifeSci Acquisition II Corp. appeared first on Legal Desire.

By

Leave a Reply

Your email address will not be published. Required fields are marked *